Stocks in Action USA: Travere Therapeutics, Daktronics, Oracle
Reading Time: 3 minutes
Travere Therapeutics (TVTX) – Stock surge after positive FDA update for kidney disease medication! Shares of Travere Therapeutics jumped on September 10 following encouraging news from the U.S. Food and Drug Administration (FDA). The company announced that no advisory meeting with an FDA expert panel is required for the approval application of its drug Filspari (Sparsentan) for the treatment of the rare kidney disease focal segmental glomerulosclerosis (FSGS) . Travere is pursuing accelerated approval with Filspari after the drug was already...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
